Gen-Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$713K Sell
3,279
-83
-2% -$18.4K 0.22% 92
2025
Q4
$768K Sell
3,362
-904
-21% -$206K 0.25% 79
2025
Q3
$988K Buy
4,266
+747
+21% +$152K 0.33% 70
2025
Q2
$653K Buy
3,519
+25
+0.7% +$4.65K 0.25% 103
2025
Q1
$732K Sell
3,494
-744
-18% -$145K 0.31% 95
2024
Q4
$753K Buy
4,238
+19
+0.5% +$3.49K 0.32% 76
2024
Q3
$850K Sell
4,219
-25
-0.6% -$4.67K 0.37% 61
2024
Q2
$728K Buy
4,244
+321
+8% +$53.2K 0.35% 63
2024
Q1
$714K Buy
+3,923
New +$676K 0.35% 63

Other funds holding ABBV

Gen-Wealth Partners's ABBV Position: Q1 2026 in Review

Gen-Wealth Partners reduced its AbbVie (ABBV) stake by 2.5% in Q1 2026, selling an estimated $18.4K and leaving 3,279 shares worth $713K. The position accounts for 0.22% of the portfolio, ranked #92.

Gen-Wealth Partners first reported a position in ABBV in Q1 2024 and has held it in 9 quarters since. The position peaked at $988K in Q3 2025. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Gen-Wealth Partners held 3,279 shares of AbbVie worth $713K as of Q1 2026.
  • Gen-Wealth Partners sold 83 AbbVie shares in Q1 2026, an estimated $18.4K.
  • AbbVie made up 0.22% of Gen-Wealth Partners's portfolio in Q1 2026, its #92 holding.
  • Gen-Wealth Partners first reported a position in AbbVie in Q1 2024 and has held it in 9 quarters since.
  • Gen-Wealth Partners's AbbVie position peaked at $988K in Q3 2025.
  • 4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.